PHAR, in collaboration with Bristol Myers Squibb, examined treatment patterns, healthcare resource utilization, and costs among patients with chronic myeloid leukemia (CML) who experienced a pleural effusion during treatment with dasatinib, a tyrosine kinase inhibitor (TKI). Their claims analysis using data from the Merative® MarketScan® Commercial and Medicare Supplemental databases aimed to understand the optimal strategy for dasatinib treatment after pleural effusion in patients with CML, which is sometimes managed by modifying the dose or changing the therapy. Their study found that dasatinib dose modification after pleural effusion was not always required, and that patients with dose modifications continued therapy for a longer duration with a lower rate of switching to another TKI versus patients who remained on a stable dose. The manuscript detailing their findings is published ahead of print in Acta Haematologica, and can be found on the PHAR publications page.